Linzagolix improves quality of life and reduces symptom severity in women with uterine fibroids (uf) who have heavy menstrual bleeding (hmb): results of two phase 3 trials

Key Points

• Linzagolix improves quality of life for women suffering from heavy menstrual bleeding caused by uterine fibroids, and reduces associated symptoms.
• The trials found that 73% of women reported a significant reduction in symptom severity after treatment with Linzagolix over a six-month period.
• Phase 3 trials evaluated the effectiveness of Linzagolix in treating uterine fibroids in a population dealing with heavy menstrual bleeding.
• The findings highlight the potential of Linzagolix as an effective therapeutic option for women facing debilitating symptoms of uterine fibroids.

Abstract